New drug treatments to restore the normal function of the RyR and NCX, and thereby prevent arrhythmogenic triggers and alternans, have the potential to provide more effective alternatives to current AF drug therapies which target voltage-gated ion channels and often have proarrhythmic side effects [39]. Here, TLX2 is linked to atrial fibrillation.